Singapore VC given options to take equity position in the company
Melbourne biotech Patrys announced today that it has secured funding of up to $15 million over the next three years to develop its lead natural human anti-body candidates into treatments for various cancers.
PAM-1 shown to reduce gastric and pancreatic tumours
Human antibody therapy specialists
Patrys announced today that is has acquired a new anti-cancer antibody which has been shown to significantly reduce gastric and pancreatic tumours in animal models of human cancers.
Two new antibody-based products added to pipeline, with animal trials starting soon.
Patrys has expanded its pipeline of antibody-based treatments for cancer with two new additions, bringing its portfolio to 13 antibodies under development.
Pre-clinical trial in ferrets of Immuron's Influenza prevention antibodies to commence before mid-year.
Antibody specialists, Immuron, are on the cusp of beginning pre-clinical trials of its Influenza prevention antibody treatment after receiving the go ahead from the CSIRO animal ethics committee.
Collaboration between Patrys and CSL sends Patrys stocks soaring.
Collaboration between Patrys and CSL sends Patrys stocks soaring.
University of Melbourne researchers collaborating with Patrys receive $300K grant for anti-cancer treatment.
University of Melbourne researchers collaborating with Patrys receive $300K grant for anti-cancer treatment.
Arana reports $181m cash, announces acting CEO
Arana reports $181m cash, announces acting CEO
